Raymond James Financial’s Organogenesis Holdings ORGO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$20.1K Sell
14,700
-172,277
-92% -$338K ﹤0.01% 5367
2026
Q2
$454K Buy
186,977
+47,335
+34% +$116K ﹤0.01% 4578
2026
Q1
$331K Sell
139,642
-281,843
-67% -$976K ﹤0.01% 4605
2025
Q4
$2.18M Buy
421,485
+4,998
+1% +$24.2K ﹤0.01% 3209
2025
Q3
$1.76M Sell
416,487
-27,753
-6% -$129K ﹤0.01% 3265
2025
Q2
$1.63M Buy
444,240
+23,919
+6% +$89.2K ﹤0.01% 3249
2025
Q1
$1.82M Buy
+420,321
New +$1.7M ﹤0.01% 3059

Other funds holding ORGO

Raymond James Financial's ORGO Position: Q3 2026 in Review

Raymond James Financial reduced its Organogenesis Holdings (ORGO) stake by 92% in Q3 2026, selling an estimated $338K and leaving 14,700 shares worth $20.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5367.

Raymond James Financial first reported a position in ORGO in Q1 2025 and has held it in 7 quarters since. The position peaked at $2.18M in Q4 2025. 123 funds tracked by Wall St. Rank hold ORGO as of Q3 2026.

  • Raymond James Financial held 14,700 shares of Organogenesis Holdings worth $20.1K as of Q3 2026.
  • Raymond James Financial sold 172,277 Organogenesis Holdings shares in Q3 2026, an estimated $338K.
  • Organogenesis Holdings made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #5367 holding.
  • Raymond James Financial first reported a position in Organogenesis Holdings in Q1 2025 and has held it in 7 quarters since.
  • Raymond James Financial's Organogenesis Holdings position peaked at $2.18M in Q4 2025.
  • 123 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.